Diagnosis and resection of an oral contraceptive-suppressible Sertoli-Leydig cell tumor with preservation of fertility and a 7-year follow-up
| Autor: | SS Shapiro, J Loughlin, Ray V. Haning |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
medicine.medical_specialty
business.industry Virilization Obstetrics and Gynecology Dehydroepiandrosterone General Medicine Mestranol chemistry.chemical_compound Endocrinology Dehydroepiandrosterone sulfate chemistry Internal medicine medicine Androstenedione medicine.symptom business Luteinizing hormone Testosterone Sertoli-Leydig Cell Tumor medicine.drug |
| Zdroj: | International Journal of Gynecology & Obstetrics. 30:195-196 |
| ISSN: | 0020-7292 |
| Popis: | A 21-year-old white woman presented with virilization, hirsutism, and acne of 1.5 years' duration. Endocrine testing demonstrated complete suppression of serum testosterone, from 5.3 to 0.6 ng/mL, and serum androstenedione, from 4.7 to 1.7 ng/mL, after oral administration of 50 micrograms of mestranol and 1 mg of norethindrone for 21 days. No suppression of either steroid was produced by dexamethasone, whereas serum dehydroepiandrosterone sulfate was suppressed from 5.2 to 1.9 micrograms/mL. A left salpingo-oophorectomy was performed for a 3 x 4-cm Sertoli-Leydig cell tumor of intermediate differentiation. Intraoperative studies demonstrated that the tumor secreted testosterone, androstenedione, 17 alpha-hydroxyprogesterone, and estradiol, but not dehydroepiandrosterone sulfate. These findings support the thesis that hormonal manipulation tests cannot differentiate between adrenal and ovarian virilizing tumors. Nor does the oral contraceptive suppression of testosterone secretion exclude an ovarian malignancy. The patient remains free of recurrence after 7 years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text